EE05086B1 - Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus - Google Patents

Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Info

Publication number
EE05086B1
EE05086B1 EEP200100252A EEP200100252A EE05086B1 EE 05086 B1 EE05086 B1 EE 05086B1 EE P200100252 A EEP200100252 A EE P200100252A EE P200100252 A EEP200100252 A EE P200100252A EE 05086 B1 EE05086 B1 EE 05086B1
Authority
EE
Estonia
Prior art keywords
primidine
derivatives
preparation
combination
product
Prior art date
Application number
EEP200100252A
Other languages
English (en)
Estonian (et)
Inventor
Adriaan Jan Janssen Paul
Joseph Kukla Michael
De Corte Bart
Ren De Jonge Marc
Heeres Jan
Yung Ho Chih
W. Kavash Robert
Maria Henricus Koymans Lucien
William Ludovici Donald
Jeanne Alfons Van Aken Koen
Jozef Lodewijk Marcel Andries Koenraad
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05086(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200100252A publication Critical patent/EE200100252A/xx
Publication of EE05086B1 publication Critical patent/EE05086B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200100252A 1998-11-10 1999-09-24 Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus EE05086B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
EE200100252A EE200100252A (et) 2002-10-15
EE05086B1 true EE05086B1 (et) 2008-10-15

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100252A EE05086B1 (et) 1998-11-10 1999-09-24 Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Country Status (41)

Country Link
US (5) US6878717B2 (enExample)
EP (2) EP1270560B1 (enExample)
JP (1) JP3635238B2 (enExample)
KR (1) KR100658489B1 (enExample)
CN (1) CN1214013C (enExample)
AP (1) AP1683A (enExample)
AR (1) AR024227A1 (enExample)
AT (2) ATE455107T1 (enExample)
AU (2) AU762523C (enExample)
BG (1) BG65103B1 (enExample)
BR (1) BRPI9915552B8 (enExample)
CA (1) CA2350801C (enExample)
CY (1) CY2008021I1 (enExample)
CZ (1) CZ301367B6 (enExample)
DE (3) DE69941934D1 (enExample)
DK (1) DK1002795T3 (enExample)
EA (1) EA004049B1 (enExample)
EE (1) EE05086B1 (enExample)
ES (2) ES2193664T3 (enExample)
FR (1) FR09C0004I2 (enExample)
HK (1) HK1048817B (enExample)
HR (2) HRP20080359B1 (enExample)
HU (2) HU227453B1 (enExample)
ID (1) ID28376A (enExample)
IL (2) IL143023A0 (enExample)
LT (1) LTC1002795I2 (enExample)
LU (1) LU91528I2 (enExample)
MY (1) MY121108A (enExample)
NL (1) NL300373I2 (enExample)
NO (3) NO318801B1 (enExample)
NZ (1) NZ511116A (enExample)
OA (1) OA11674A (enExample)
PL (1) PL204427B1 (enExample)
PT (1) PT1002795E (enExample)
SI (1) SI1002795T1 (enExample)
SK (2) SK287269B6 (enExample)
TR (1) TR200101306T2 (enExample)
TW (1) TWI238161B (enExample)
UA (1) UA70966C2 (enExample)
WO (1) WO2000027825A1 (enExample)
ZA (1) ZA200103769B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143023A0 (en) * 1998-11-10 2002-04-21 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
TR200200763T2 (tr) * 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
CN1302418C (zh) * 2000-11-01 2007-02-28 斯雷普内姆斯·Com公司 集成注册机构的互联网域名获取系统
RU2330024C2 (ru) 2001-05-29 2008-07-27 Шеринг Акциенгезельшафт Ингибирующие cdk-киназы пиримидины, способ их получения и их применение в качестве лекарственных средств
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
DE50212771D1 (de) 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
NZ531855A (en) 2001-11-01 2005-12-23 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
NZ531853A (en) 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04007776A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
EP1485364B1 (en) 2002-03-13 2009-03-11 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN1290893C (zh) * 2002-05-03 2006-12-20 詹森药业有限公司 聚合物微乳状液
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
ES2677769T3 (es) * 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Subunidad secuestrante y composiciones y procedimientos relacionados
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7585861B2 (en) * 2003-02-07 2009-09-08 Janssen Pharmaceutica, N.V. HIV inhibiting 1,2,4-triazines
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
WO2004074244A2 (en) * 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0412734A (pt) 2003-07-17 2006-09-26 Tibotec Pharm Ltd processo para preparação de partìculas que contêm um antiviral
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
AU2004274185B2 (en) 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US8099262B2 (en) 2004-03-02 2012-01-17 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006015985A1 (en) 2004-08-10 2006-02-16 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
ES2371923T3 (es) * 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
CN101027288B (zh) * 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
CN101031550B (zh) 2004-09-30 2015-05-27 泰博特克药品有限公司 抑制hiv的5-碳环-或杂环取代的嘧啶类
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
JP5095409B2 (ja) 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
WO2006079656A1 (en) * 2005-01-27 2006-08-03 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
ATE398613T1 (de) 2005-02-16 2008-07-15 Astrazeneca Ab Chemische verbindungen
MX2007010051A (es) * 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
HRP20100504T1 (hr) * 2005-03-04 2010-10-31 Tibotec Pharmaceuticals 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
RU2458056C2 (ru) * 2005-05-26 2012-08-10 Тиботек Фармасьютикалз Лтд Способ получения 4-(1,6-дигидро-6-оксо-2-пиримидинил)амино-бензонитрила
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7754773B2 (en) * 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
ES2391783T3 (es) 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
US7834025B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
ES2327972T3 (es) 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CA2645959C (en) 2006-03-30 2016-05-17 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
MX2008012576A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
NZ572702A (en) 2006-06-06 2011-09-30 Tibotec Pharm Ltd Process for preparing spray dried formulations of etravirine in microcrystalline cellulose
SI2034975T1 (sl) 2006-06-19 2012-07-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
EA020749B1 (ru) 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
BRPI0720858B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009079521A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK2300013T4 (da) 2008-05-21 2025-02-03 Takeda Pharmaceuticals Co Phosphorderivater som kinasehæmmere
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010038081A2 (en) * 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
EP2413936B1 (en) 2009-03-30 2016-11-02 Janssen Sciences Ireland UC Co-crystal of etravirine and nicotinamide
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
JP5406934B2 (ja) 2009-06-22 2014-02-05 エムキュア ファーマシューティカルズ リミテッド ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
WO2012001695A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etra virine intermediate and polymorphs of etravirine
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
TWI545115B (zh) 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AR083813A1 (es) 2010-11-10 2013-03-27 Hoffmann La Roche Derivados de pirazol aminopirimidina como moduladores de lrrk2
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
WO2012147104A1 (en) 2011-04-26 2012-11-01 Mylan Laboratories Ltd Novel process for the preparation of etravirine
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
WO2013028818A1 (en) 2011-08-23 2013-02-28 Endo Pharmaceuticals Inc. Pyrimido- pyridazinone compounds and use thereof
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
KR102090453B1 (ko) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 염
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9375411B2 (en) 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
EP3310760B8 (en) 2015-06-22 2022-10-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
EP3615032A4 (en) 2017-04-28 2020-12-23 Asana BioSciences, LLC FORMULATIONS, METHODS, KITS AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVING THE STABILITY OF AN ACTIVE PHARMACEUTICAL COMPONENT
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
DE3581570D1 (de) * 1984-06-25 1991-03-07 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
KR950006713B1 (ko) 1988-03-31 1995-06-21 미쓰비시 가세이 가부시끼가이샤 6-치환 비환식 피리미딘뉴클레오시드 유도체 및 그 유도체를 유효성분으로 하는 항 비루스제
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
ES2193660T3 (es) * 1998-03-27 2003-11-01 Janssen Pharmaceutica Nv Derivados de pirimidina inhibidores de vih.
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
IL143023A0 (en) * 1998-11-10 2002-04-21 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines
WO2001085699A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
BR9915552B1 (pt) 2013-11-19
LTPA2008016I1 (lt) 2021-04-26
US20040039005A1 (en) 2004-02-26
LU91528I9 (enExample) 2019-01-02
BG65103B1 (bg) 2007-02-28
AR024227A1 (es) 2002-09-25
IL169949A (en) 2011-02-28
EA200100536A1 (ru) 2002-02-28
OA11674A (en) 2005-01-12
ZA200103769B (en) 2002-08-12
MY121108A (en) 2005-12-30
EP1002795B1 (en) 2003-03-05
US8003789B2 (en) 2011-08-23
HRP20010161B9 (hr) 2014-10-24
DE69941934D1 (de) 2010-03-04
JP2002529456A (ja) 2002-09-10
US20080176880A1 (en) 2008-07-24
TR200101306T2 (tr) 2001-10-22
BRPI9915552B8 (pt) 2021-05-25
CY2008021I2 (el) 2010-07-28
CY2008021I1 (el) 2010-07-28
CN1322198A (zh) 2001-11-14
EE200100252A (et) 2002-10-15
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
UA70966C2 (uk) 2004-11-15
US20050288278A1 (en) 2005-12-29
IL143023A0 (en) 2002-04-21
CA2350801C (en) 2008-05-20
NO20011696L (no) 2001-04-04
NL300373I1 (nl) 2009-03-02
US7037917B2 (en) 2006-05-02
HRP20080359B1 (hr) 2016-01-01
KR20010075235A (ko) 2001-08-09
HU227453B1 (en) 2011-06-28
HK1025330A1 (en) 2000-11-10
BR9915552A (pt) 2001-08-14
EP1002795A1 (en) 2000-05-24
KR100658489B1 (ko) 2006-12-18
JP3635238B2 (ja) 2005-04-06
CN1214013C (zh) 2005-08-10
AP1683A (en) 2006-11-29
ES2193664T3 (es) 2003-11-01
EP1270560B1 (en) 2010-01-13
CZ20011533A3 (cs) 2001-10-17
ID28376A (id) 2001-05-17
HK1048817B (en) 2010-04-09
US20110263625A1 (en) 2011-10-27
EP1270560A1 (en) 2003-01-02
HRP20010161A2 (en) 2002-02-28
NL300373I2 (nl) 2009-04-01
SK287269B6 (sk) 2010-05-07
SI1002795T1 (en) 2003-10-31
NO2021015I1 (no) 2021-03-29
HUP0104177A2 (hu) 2002-03-28
NZ511116A (en) 2003-08-29
NO20011696D0 (no) 2001-04-04
ATE233740T1 (de) 2003-03-15
PT1002795E (pt) 2003-07-31
AU2011200708A1 (en) 2011-03-10
US6878717B2 (en) 2005-04-12
LU91528I2 (fr) 2009-04-20
WO2000027825A1 (en) 2000-05-18
PL204427B1 (pl) 2010-01-29
FR09C0004I1 (enExample) 2009-02-27
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
HRP20080359A2 (en) 2008-12-31
NO2009003I2 (no) 2010-06-07
SK6032001A3 (en) 2002-01-07
TWI238161B (en) 2005-08-21
CA2350801A1 (en) 2000-05-18
DE69905683T2 (de) 2004-03-18
CZ301367B6 (cs) 2010-02-03
NO318801B1 (no) 2005-05-09
EA004049B1 (ru) 2003-12-25
NO2009003I1 (no) 2009-03-09
HK1048817A1 (en) 2003-04-17
ES2338760T3 (es) 2010-05-12
HUP0104177A3 (en) 2003-01-28
DE122009000003I1 (de) 2009-05-20
PL347586A1 (en) 2002-04-08
ATE455107T1 (de) 2010-01-15
HU230394B1 (hu) 2016-04-28
FR09C0004I2 (fr) 2010-06-11
US8530655B2 (en) 2013-09-10
AU6200899A (en) 2000-05-29
BG105418A (en) 2001-11-30
HRP20010161B1 (en) 2009-03-31
AU762523B2 (en) 2003-06-26
AU762523C (en) 2004-02-12
LTC1002795I2 (lt) 2021-06-10

Similar Documents

Publication Publication Date Title
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
EE200000620A (et) 3-(amino- või aminoalküül)püridinooni derivaadid,nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE03489B1 (et) Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
FI950625A7 (fi) Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
EE9900114A (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04087B1 (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine

Legal Events

Date Code Title Description
AA1Y Spc filed

Free format text: PRODUCT NAME: INTELENCE - ETRAVIRINE; REGISTRATION NO/DATE: C(2008)4744 20080828

Spc suppl protection certif: C20080006

Filing date: 20081211

FG1Y Spc granted

Free format text: PRODUCT NAME: INTELENCE - ETRAVIRINE; REGISTRATION NO/DATE: C(2008)4744 20080828

Spc suppl protection certif: C20080006 00021

Filing date: 20081211

Extension date: 20230828

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCZ Extension of supplementary protection certificate: granted [paediatric extension]

Free format text: PRODUCT NAME: ETRAVIRIIN; NATIONAL AUTHORISATION NUMBER: EMA/CHMP/143595/2020; DATE OF AUTHORISATION: 20200326

Spc suppl protection certif: C20080006

Extension date: 20240301